• Drug: Aflibercept
• The Panorama study involves a dosing regimen on intravitreal administration of an anti-VEGF drug to slow the worsening of nonproliferative diabetic retinopathy (NPDR). This drug prevents vision loss due to the damage of blood vessels in the retina. These fragile vessels leak into the vitreous cavity and can cause retinal traction or detachment. By slowing the progression of NPDR, further vision-threatening diseases such as proliferative diabetic retinopathy and diabetic macular edema can be prevented.
The overall objective of the NEI Mentored Clinical Scientist Development Program Award at UCSD is to develop outstanding clinician scientists to successfully compete at the national level for NIH grants and emerge as leaders within academic Ophthalmology. Through this institutional career development award, we will mentor clinician scientists toward independent academic appointments in ophthalmology.
The information contained in this online site is intended to provide accurate and helpful health information for the general public. It is made available with the understanding that the author and publisher are not engaged in rendering medical, health, psychological, or any other kind of personal professional services on this site. The information should not be considered complete and does not cover all diseases, ailments, physical conditions or their treatment. It should not be used in place of a call or visit to a medical, health or other competent professional, who should be consulted before adopting any of the suggestions in this site or drawing inferences from it.
The information about drugs contained on this site is general in nature. It does not cover all possible uses, actions, precautions, side effects, or interactions of the medicines mentioned, nor is the information intended as medical advice for individual problems or for making an evaluation as to the risks and benefits of taking a particular drug.
The operator(s) of this site, and the publisher, specifically disclaim all responsibility for any liability, loss or risk, personal or otherwise, which is incurred as a consequence, directly or indirectly, of the use and application of any of the material on this site.
Click Here To Accept